- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | Vivesto AB: Vivesto reports positive Paccal Vet cat topline results supporting continued clinical development | 458 | GlobeNewswire (Europe) | Solna, Sweden, 17, 2026 - Vivesto AB, an oncology-focused development company, today announced positive topline results from its Paccal Vet dose-finding study in cats with solid tumors. The study demonstrates... ► Artikel lesen | |
| VIVESTO Aktie jetzt für 0€ handeln | |||||
| 15.09. | Vivesto AB: Vivesto's positive dog topline results support continued development and strengthen partnering prospects for Paccal Vet | 209 | GlobeNewswire (Europe) | Solna, Sweden, September 15, 2026 - Vivesto AB, an oncology-focused development company, today announced positive topline results from its open label clinical pilot study evaluating Paccal Vet in dogs... ► Artikel lesen | |
| 13.08. | Vivesto AB Q2 Loss Declines | 3 | RTTNews | ||
| 01.07. | Vivesto AB: Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose | 282 | GlobeNewswire (Europe) | Solna, Sweden, July 1, 2026 - Vivesto AB, an oncology-focused development company, today announced that recruitment has been completed in the company's ongoing Paccal Vet dose-finding study in cats... ► Artikel lesen | |
| 26.06. | Vivesto AB: Vivesto completes recruitment in Paccal Vet dog pilot study - topline results expected Q3 2026 | 375 | GlobeNewswire (Europe) | Solna, Sweden, June 26, 2026 - Vivesto AB, an oncology-focused development company, today announced the completion of recruitment in its clinical Paccal Vet pilot study in dogs with splenic hemangiosarcoma... ► Artikel lesen | |
| 16.06. | Vivesto AB: Vivesto reports positive results from i.v. Cantrixil PK/toxicology study | 226 | GlobeNewswire (Europe) | Solna, Sweden, June 16, 2026 - Vivesto AB, an oncology-focused development company, today reports positive results from its exploratory pharmacokinetic (PK) and toxicology study with Cantrixil. The... ► Artikel lesen | |
| 05.06. | Vivesto AB: Vivesto appoints Björn Svanström as CFO | 267 | GlobeNewswire (Europe) | Solna, Sweden, June 5, 2026 - Vivesto AB, an oncology-focused development company, today announces that Björn Svanström was appointed as the new Chief Financial Officer (CFO). Björn Svanström will take... ► Artikel lesen | |
| 20.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 20.05.2026 | 992 | Xetra Newsboard | The following instruments on XETRA do have their first trading 20.05.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.05.2026
Aktien
1 CH1107979838 R&S Group Holding AG
2... ► Artikel lesen | |
| 19.05. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.05.2026 | 784 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 19.05.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.05.2026ISIN NameIE000YUAPTQ0 KRELVEFUMOSCR... ► Artikel lesen | |
| 19.05. | XFRA ISIN CHANGE | 492 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenSE0000722365 Vivesto AB 19.05.2026 SE0028925701 Vivesto AB 20.05.2026 Tausch 100:1NO0013178616 Public Property Invest... ► Artikel lesen | |
| 19.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 19.05.2026 | 472 | Xetra Newsboard | Das Instrument 74I CA13536V1076 CANADIAN BANC CORP CL.A EQUITY wird ex Kapitalmassnahme gehandelt am 19.05.2026 The instrument 74I CA13536V1076 CANADIAN BANC CORP CL.A EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 15.05. | Split and Change of ISIN for Vivesto AB | 584 | GlobeNewswire | The company will carry out a reverse stock split in a ratio of 1:100. The share will be traded under new ISIN code with effect from May 20, 2026. The order book will not change.
... ► Artikel lesen | |
| 13.05. | Vivesto AB: Vivesto announces timetable for reverse share split | 280 | GlobeNewswire (Europe) | At the Annual General Meeting in Vivesto AB ("Vivesto" or the "Company") on 7 May 2026, it was resolved to carry out a reverse share split of 1:100, entailing that one hundred (100) shares are consolidated... ► Artikel lesen | |
| 07.05. | Vivesto AB: Report from Annual General Meeting in Vivesto AB | 359 | GlobeNewswire (Europe) | At the Annual General Meeting in Vivesto AB ("Vivesto" or the "company") held on 7 May 2026, the following resolutions were passed. All resolutions were in accordance with the proposals, described in... ► Artikel lesen | |
| 01.04. | Vivesto AB: The Board of Directors of Vivesto proposes a reverse share split and reduction of the share capital | 207 | GlobeNewswire (Europe) | The Board of Directors of Vivesto AB ("Vivesto" or the "Company") has resolved to propose that the Annual General Meeting on 7 May 2026 resolves on a reverse share split, whereby one hundred (100) existing... ► Artikel lesen | |
| 13.03. | Vivesto AB: First dogs dosed in Vivesto's PK/toxicology study with Cantrixil | 388 | GlobeNewswire (Europe) | Solna, Sweden, March 13, 2026 - Vivesto AB, an oncology-focused development company, today announces that the first dogs have been dosed in the company's ongoing pharmacokinetic (PK) and toxicology... ► Artikel lesen | |
| 27.02. | The observation status for Vivesto AB is removed | 285 | GlobeNewswire | On November 20, 2025, the shares in Vivesto AB (the "Company") were given observation status with reference to uncertainty in respect of the issuer's financial position.
Today, February 27,... ► Artikel lesen | |
| 23.01. | Vivesto AB: Vivesto announces outcome of the rights issue | 341 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 02.01. | Vivesto AB: Vivesto publishes information document regarding the rights issue | 448 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE... ► Artikel lesen | |
| 31.12.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025 | 1.550 | Xetra Newsboard | Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| MERCK KGAA | 136,90 | +1,82 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| GILEAD SCIENCES | 128,68 | +0,09 % | Assembly Biosciences: Herpes-Countdown mit Gilead | ||
| AURORA CANNABIS | 3,518 | +0,86 % | Aurora Cannabis: Beschwerde bringt den Deal ins Wanken | ||
| CANOPY GROWTH | 0,780 | +0,72 % | Canopy Growth Corporation: Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany | Mr. Blöte's appointment strengthens Canopy Growth's commercial leadership as it drives growth across its European medical cannabis businessCanopy Growth Corporation ("Canopy Growth", "our", "we" or... ► Artikel lesen | |
| STADA ARZNEIMITTEL | - | - | Biosimilars: Stada: Pembrolizumab aus China | ||
| ASTRAZENECA | 139,30 | 0,00 % | Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy | ||
| TILRAY BRANDS | 3,215 | +0,31 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 34,600 | -1,14 % | XFRA TEVA: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILTEVA PHARMACEUT.... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 448,45 | +0,04 % | $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen | |
| ZOETIS | 61,98 | +0,10 % | Zoetis: Diese Sorge bremst die Comeback-Fantasie | ||
| CRONOS GROUP | 2,896 | +1,05 % | Cronos Group Inc.: Cronos Group Reports 2026 Second Quarter Results | Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis... ► Artikel lesen | |
| DOCMORRIS | 13,840 | -0,36 % | Aktien Europa: Moderate Gewinne - Ölpreise etwas gesunken | PARIS/LONDON/ZÜRICH (dpa-AFX) - Europas Aktienmärkte haben sich am Dienstag nach verhaltenem Start robust gezeigt. Nach Ansicht von Marktanalyst Andreas Lipkow vom Broker CMC Markets bleiben die Anleger... ► Artikel lesen |
VIVESTO AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,002 (-0,29 %) liegt der Kurs bei 0,688 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVESTO AB finden Sie auf Wallstreet Online.